UnitedHealth’s UHNW stock is trading near its 52-week high at about $425.6 per share, yet analysts see the valuation reset from 23.1 times this year’s expected earnings to about 17.0 times by 2028. That gap leaves investors judging the same stock two ways at once: expensive on near-term earnings, cheaper on the earnings power analysts expect three years out.
23.1 times versus 17.0 times is a 26% drop in the earnings multiple over three years, and the math depends on analysts’ forecast that earnings can grow about 16.5% a year while revenue rises 4.3% a year. If those estimates hold, the share price can sit near today’s level while the earnings denominator rises underneath it, pulling the valuation lower without requiring the stock to fall.
UnitedHealth’s 2026 earnings gap
9.7% revenue growth over the last twelve months gives the forecast some backing, but the next checkpoint is tighter: management guided 2026 adjusted earnings to about 18.2 per share, while the analyst consensus sits at $18.39 per share. That is a narrow spread, and it tells investors the market is already asking whether UnitedHealth can keep pace with the growth rate needed to justify the lower 2028 multiple.
18.2 per share versus $18.39 per share leaves little room for a miss, especially with the stock already priced near $425.6. For valuation-focused holders, the practical question is not whether the shares look cheap today; it is whether the company can keep compounding fast enough to make the current price look less demanding over time.
UnitedHealthcare and Optum Health
The latest quarterly backdrop helps explain why some of that future growth is still plausible. UnitedHealthcare and Optum Health are both moving in the right direction, with pricing improving relative to elevated health care cost trends and operational improvements taking hold, while the medical care ratio improved in the first quarter.
72% is the size of the drop UnitedHealth has suffered in past market shocks from peak to trough, a reminder that this stock has never been a one-way trade. A scenario using a 20.1 times multiple by 2028 would put the stock about 18% higher than today, but that outcome still depends on earnings growth staying on track and the medical care ratio continuing to improve.
17.0 times is where analysts now place the 2028 earnings multiple, and that leaves the stock at a point where the debate is less about the label on today’s price and more about the earnings path underneath it. Investors in UnitedHealth are really being asked to decide whether 16.5% annual earnings growth is enough to keep the valuation moving lower on paper while the business itself keeps expanding.
